Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by GoldenInvestoron Mar 15, 2024 10:58am

124 Views

Post# 35934841

Morgan Stanley CIO on AI & drug discovery

Morgan Stanley CIO on CNBC speaking to how AI can help benefit healthcare via drug discovery.

Once drugs are discovered, then they have to be produced.

With 3 manufacturing facilities and a r&d facility available to pivot to new drug production, this could be a GUD & large opportunity to continue to ramp up & grow production

Pharma & AI connections …

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity